<?xml version="1.0" encoding="UTF-8"?>
<p>A “cytokine storm” has been proposed several times as responsible for COVID‐19 lethality (e.g., Moccia et al., 
 <xref rid="bph15207-bib-0061" ref-type="ref">2020</xref>; Qin et al., 
 <xref rid="bph15207-bib-0068" ref-type="ref">2020</xref>) and, consequently, the anti‐IL‐6 receptor antibody, 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881" xmlns:xlink="http://www.w3.org/1999/xlink">tocilizumab</ext-link> (used for the treatment of rheumatoid arthritis and CRS after CAR‐T therapies; Alvi et al., 
 <xref rid="bph15207-bib-0007" ref-type="ref">2019</xref>), has been proposed in many clinical studies, and it is now in Phase II and Phase III studies in COVID‐19 patients (Lu, Chen, &amp; Chang, 
 <xref rid="bph15207-bib-0056" ref-type="ref">2020</xref>; Luo et al., 
 <xref rid="bph15207-bib-0058" ref-type="ref">2020</xref>). Monoclonal antibodies, anti‐IL‐1 and anti‐IL‐6, and plasma derived from COVID‐19 recovered patients have been proposed (
 <ext-link ext-link-type="uri" xlink:href="https://www.sciencenews.org/article/coronavirus-covid-19-can-plasma-recovered-patients-treat-sick" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.sciencenews.org/article/coronavirus-covid-19-can-plasma-recovered-patients-treat-sick</ext-link>). Other anti‐inflammatory drugs, including JAK inhibitors, and glucocorticoids may also be useful (Zhang et al., 
 <xref rid="bph15207-bib-0087" ref-type="ref">2020</xref>). Indeed, a preliminary study showed that 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768" xmlns:xlink="http://www.w3.org/1999/xlink">dexamethasone</ext-link> was able to reduce 28‐day mortality among COVID‐19 patients receiving invasive mechanical ventilation (Horby et al., 
 <xref rid="bph15207-bib-0038" ref-type="ref">2020</xref>). Also, blockade of the kallikrein‐kinin system, upstream of bradykinin, by 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9094" xmlns:xlink="http://www.w3.org/1999/xlink">lanadelumab</ext-link> (already used in hereditary angioedema) has been proposed for COVID‐19 patients (Colarusso et al., 
 <xref rid="bph15207-bib-0017" ref-type="ref">2020</xref>). Promising drugs are blockers of TMPRSS2, such as 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432" xmlns:xlink="http://www.w3.org/1999/xlink">camostat</ext-link> mesylate and 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262" xmlns:xlink="http://www.w3.org/1999/xlink">nafamostat</ext-link> mesylate (see Zhou, Fang, et al., 
 <xref rid="bph15207-bib-0090" ref-type="ref">2020</xref>).
</p>
